SNBL USA is in a unique position to perform ARS studies, from demonstration of efficacy in representative animal models, to pivotal nonclinical studies under the FDA’s Animal Rule.
We are proud of SNBL’s long history of excellence and leadership across our multiple product and service offerings; but more importantly, we benchmark our true success by what we achieve for our customers today and what we do to enable a better future for patients and their families tomorrow.Read More
SNBL USA is a wholly-owned subsidiary of Shin Nippon Biomedical Laboratories, Ltd. (SNBL), one of the largest CROs in Japan. With its multiple worldwide facilities and countless skilled and experienced scientists and technicians, SNBL Group works together in providing a full range of drug development services.
As a drug class, Nucleic Acid-based Therapeutics represents a diverse spectrum of chemistry, constructs, and delivery options.
Blending our strengths, SNBL USA’s laboratory services division represents a powerful resource to extend discovery and development capabilities while still providing superior, individualized service to each client.
Dr. Thrall, Manager and Senior Study Director for SNBL USA’s Acute Radiation Syndrome (ARS) Program, is scheduled to present a poster at the upcoming Radiation Research Society (RRS) Annual Meeting. RRS is taking place in Westin, Florida, September 19-22, 2015. If you are scheduled to attend, stop by Booth #10 and connect with SNBL USA’s ARS Team.Read More
The SNBL USA ARS Advisory Board is comprised of leaders in the fields of Radiation Research and Biology. The Board held its initial meeting on June 23, 2015 where it deliberated on several topics of strategic importance to SNBL. Their mission is to provide a unique scientific resource for both ongoing scientific issues and for our overall Program needs. A thorough discussion was conducted regarding the development of animal models, qualification strategies for new capabilities, the applicability of various species and models for comparative pathobiology, the refinement of current approaches...Read More
It is a pleasure to announce Li Zhan, MD, PhD, DABT has joined SNBL USA as a Study Director and newest member of our safety assessment team. In this role Dr. Zhan will be designated as the single point of control for assigned GLP and non-GLP studies performed. He will be responsible for the interpretation, analysis, documentation, and reporting of study results while ensuring the quality standards maintained by SNBL USA.Read More